Data / Research funding / Ohio / Janusq, LLC
Janusq, LLC: 4 NIH awards ($1.6M), fiscal years 2021 to 2026
Janusq, LLC in Rocky River, OH is funded under 4 NIH awards ($1.6M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- DKRHA61KMNX4
- State
- Ohio
Awards
4 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of Alzheimer's disease | NIH | National Institute on Aging | 2025 | $576,664 | September 22, 2025 | March 31, 2027 | SCHILB, ANDREW LORING | reporter.nih.gov |
| In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $490,501 | September 15, 2025 | February 28, 2027 | SCHILB, ANDREW LORING | reporter.nih.gov |
| Pharmacokinetic and pharmacodynamic assessment of peptide-based therapy DA1 for the treatment of Alzheimer's disease | NIH | National Institute on Aging | 2022 | $259,584 | September 30, 2022 | August 31, 2024 | SCHILB, ANDREW LORING | reporter.nih.gov |
| Pharmacokinetic Assessment of Peptide-Based Therapy HV-3 for the Treatment of Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $240,938 | December 15, 2020 | May 31, 2023 | SCHILB, ANDREW LORING | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 2 | $1,067,165 | 0 | $0 |
| 2022 | 1 | $259,584 | 0 | $0 |
| 2021 | 1 | $240,938 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | PAR-25-095 | NIH | 93.866 | November 6, 2026 | $350,000 | Same assistance listing 93.866 as 2 awards here |
| Functional Target Validation for Alzheimer's Disease-Related Dementias | RFA-NS-26-034 | NIH | 93.853 | November 6, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required) | PAR-27-007 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) | RFA-AG-27-010 | NIH | 93.866 | November 10, 2026 | Not listed | Same assistance listing 93.866 as 2 awards here |
| Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) | RFA-NS-26-001 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) | RFA-NS-26-030 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | PAR-25-096 | NIH | 93.866 | November 17, 2026 | $200,000 | Same assistance listing 93.866 as 2 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) | PAR-25-052 | NIH | 93.853 | November 19, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.853 | November 23, 2026 | $375,000 | Same assistance listing 93.853 as 2 awards here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.866 | November 24, 2026 | Not listed | Same assistance listing 93.866 as 2 awards here |
| Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) | RFA-OD-27-008 | NIH | 93.853 | December 2, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.853 | December 3, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.853 | December 3, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.853 | December 4, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.866 | January 5, 2027 | Not listed | Same assistance listing 93.866 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.866 | January 5, 2027 | Not listed | Same assistance listing 93.866 as 2 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.853 | January 7, 2027 | $375,000 | Same assistance listing 93.853 as 2 awards here |
| Intervention Research to Improve Native American Health (R34 Clinical Trial Optional) | PAR-25-378 | NIH | 93.866 | January 7, 2027 | Not listed | Same assistance listing 93.866 as 2 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.